Equity Overview
Price & Market Data
Price: $0.241
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $189,645,504
Daily Volume: 0
Performance Metrics
1 Week: -0.21%
1 Month: -9.79%
3 Months: -5.39%
6 Months: 78.75%
1 Year: 91.79%
YTD: 78.75%
Company Details
Employees: 98
Sector: Commercial services
Industry: Miscellaneous commercial services
Country:
Details
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.